The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma. Pharmacokinetic (PK) properties will be explored and tumor responses to treatment will be evaluated.
Phase 1/Phase 2
Estimated Primary Completion Date
- Drug: VAL-083 (Dianhydrogalactitol)
DelMar Pharmaceuticals, Inc.